ArticlePloS one2020

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.

Amanda Hanson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.